Advertisement

The Role of Radiation Therapy

  • Andre Tsin Chih Chen
  • Carlos Bo Chur Hong
Chapter

Abstract

The Intergroup 0116 (INT 0116) has established chemoradiation as the standard treatment for resected gastric cancer in Western countries. More recently, there has been a debate on the role of radiation in the treatment of diffuse-type adenocarcinoma of the stomach. Here we discuss the evidence and controversies that surround this issue. At this point of current knowledge, we recommend adjuvant chemoradiation for the treatment of resected diffuse-type adenocarcinoma of the stomach.

Keywords

Gastric Cancer Diffuse Adjuvant Chemoradiation Radiotherapy 

Abbreviations

5-FU + LV

5-fluorouracil plus leucovorin

CMT

Chemotherapy

CRT

Chemoradiation

CT

Computerized tomography

DFS

Disease-free survival

Gy

Gray

HR

Hazard ratio

OR

Odds ratio

OS

Overall survival

RFS

Relapse-free survival

RT

Radiation therapy

XP

Capecitabine and cisplatin

XRT

Capecitabine with radiation therapy

References

  1. 1.
    Gunderson LL, Sosin H. Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys. 1982;8(1):1–11.CrossRefPubMedGoogle Scholar
  2. 2.
    Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–30.CrossRefPubMedGoogle Scholar
  3. 3.
    Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;30(19):2327–33.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Dent DM, Madden MV, Price SK. Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. Br J Surg. 1988;75(2):110–2.CrossRefPubMedGoogle Scholar
  5. 5.
    Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group Br J Cancer. 1999;79(9–10):1522–30.PubMedGoogle Scholar
  6. 6.
    Viste A, Svanes K, Janssen CW Jr, Maartmann-Moe H, Søreide O. Prognostic importance of radical lymphadenectomy in curative resections for gastric cancer. Eur J Surg. 1994;160(9):497–502.PubMedGoogle Scholar
  7. 7.
    Siewert JR, Böttcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg. 1998;228(4):449–61.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11(5):439–49.CrossRefPubMedGoogle Scholar
  9. 9.
    Lee J, Lim DH, Kim S, Park SH, Park JO, Park YS, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30(3):268–73.CrossRefPubMedGoogle Scholar
  10. 10.
    Park SH, Sohn TS, Lee J, do DH L, Hong ME, Kim KM, et al. Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses. J Clin Oncol. 2015;33(28):3130–6.CrossRefPubMedGoogle Scholar
  11. 11.
    Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84.CrossRefPubMedGoogle Scholar
  13. 13.
    Shapiro J, van Lanschot JJ, Hulshof MC, van Hagen P, van Berge Henegouwen MI, Wijnhoven BP, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090–8.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Stessin AM, Sison C, Schwartz A, Ng J, Chao CK, Li B. Does adjuvant radiotherapy benefit with diffuse-type gastric cancer? Results from the surveillance, epidemiology, and end results database. Cancer. 2014;120(22):3562–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Dai Q, Jian L, Lin RJ, Wei KK, Gan LL, Deng CH, et al. Adjuvant chemoradiotherapy versus chemotherapy for gastric cancer: a meta-analysis of randomized controlled trials. J Surg Oncol. 2015;111(3):277–84.CrossRefPubMedGoogle Scholar
  16. 16.
    Marrelli D, Roviello F, de Manzoni G, Morgagni P, Di Leo A, Saragoni L, et al. Italian research Group for Gastric Cancer. Different patterns of recurrence in gastric cancer depending on Lauren’s histological type: longitudinal study. World J Surg. 2002;26(9):1160–5.Google Scholar
  17. 17.
    Vasconcelos K, Chen ATC, Hong CBC, Nakazato D, Stelko G, Hoff PMG, et al. Liver irradiation increases relapse-free survival in adjuvant gastric cancer treatment. Int J Radiat Oncol Biol Phys. 2013;87(2 Suppl 2257):S301.CrossRefGoogle Scholar
  18. 18.
    Park SH, Lee SJ, Kim ST, Lee J, Park JO, Park YS, et al. Multicenter phase III trial of adjuvant chemoradiotherapy in stomach tumors 2 (ARTIST 2). J Clin Oncol. 2015;33(Suppl 3):TPS228.CrossRefGoogle Scholar
  19. 19.
    Verheij M, Jansen EPM, Cats A, van Grieken NCT, Aaronson NK, Boot H, et al. A multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer: First results from the CRITICS study. J Clin Oncol. 2016;34(Suppl 15):4000.CrossRefGoogle Scholar
  20. 20.
  21. 21.
    Tepper JE, Gunderson LL. Radiation treatment parameters in the adjuvant postoperative therapy of gastric cancer. Semin Radiat Oncol. 2002;12(2):187–95.CrossRefPubMedGoogle Scholar
  22. 22.
    Ashman JB, Callister MD, Jaroszewski DE, Ross HJ, Ezzell GA, Gunderson LL. Trimodality therapy for distal esophageal/esophagogastric junction adenocarcinoma using three-dimensional conformal and intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2010;78(3 Suppl 2222):S303.CrossRefGoogle Scholar
  23. 23.
    Chopra S, Agarwal A, Engineer R, Dora T, Thomas B, Sonawone S, et al. Intensity modulated radiation therapy (IMRT) is not superior to three-dimensional conformal radiation (3DCRT) for adjuvant gastric radiation: a matched pair analysis. J Cancer Res Ther. 2015;11(3):623–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Trip AK, Nijkamp J, van Tinteren H, Cats A, Boot H, Jansen EP, et al. IMRT limits nephrotoxicity after chemoradiotherapy for gastric cancer. Radiother Oncol. 2014;112(2):289–94.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Instituto do Câncer do Estado de São PauloSão PauloBrazil
  2. 2.Faculdade de Medicina da Universidade de São Paulo/Instituto do Câncer do Estado de São PauloSão PauloBrazil

Personalised recommendations